Yenidoğanlarda Akut Metabolik Bozuklukların Yönetimi
Özet
Yenidoğanlarda akut metabolik bozukluklar, çoğu zaman sepsis, hipoksik iskemik ensefalopati veya beslenme intoleransı gibi sık görülen neonatal durumları taklit eden, hızlı tanı ve tedavi gerektiren klinik tablolardır. Kalıtsal metabolik hastalıklar; toksik metabolit birikimi, enerji üretiminde yetersizlik veya kompleks molekül metabolizmasındaki bozukluklar sonucunda ortaya çıkabilir. Yenidoğan döneminde açıklanamayan hipoglisemi, yüksek anyon açıklı metabolik asidoz, hiperamonyemi, dirençli nöbet, ensefalopati, karaciğer yetmezliği veya kolestatik sarılık varlığında metabolik hastalıklar mutlaka ayırıcı tanıda düşünülmelidir. Tanısal yaklaşımda kritik örneklerin doğru zamanda alınması, biyokimyasal paternlerin değerlendirilmesi ve metabolik tetkiklerin hızlandırılması temel basamaklardır. Tedavide amaç katabolizmayı durdurmak, yeterli glukoz desteği sağlamak, toksik metabolit birikimini azaltmak ve organ hasarını önlemektir. Organik asidemi, üre siklus defektleri, galaktozemi, tirozinemi tip I, piridoksin bağımlı epilepsi ve nonketotik hiperglisinemi gibi bazı hastalıklarda erken tanı ve özgül tedavi prognozu belirgin şekilde etkileyebilir.
Acute metabolic disorders in neonates often mimic common neonatal conditions such as sepsis, hypoxic-ischemic encephalopathy, or feeding intolerance and require prompt recognition and management. Inherited metabolic diseases may result from toxic metabolite accumulation, impaired energy production, or defects in complex molecule metabolism. In the neonatal period, unexplained hypoglycemia, high anion gap metabolic acidosis, hyperammonemia, refractory seizures, encephalopathy, liver failure, or cholestatic jaundice should raise suspicion for an underlying metabolic disorder. A systematic diagnostic approach includes timely collection of critical samples, interpretation of biochemical patterns, and prioritization of metabolic investigations. The main goals of treatment are to stop catabolism, provide adequate glucose support, reduce toxic metabolite accumulation, and prevent irreversible organ damage. Early diagnosis is particularly important in treatable conditions such as organic acidemias, urea cycle disorders, galactosemia, tyrosinemia type I, pyridoxine-dependent epilepsy, and nonketotic hyperglycinemia, in which disease-specific therapy may significantly improve clinical outcomes.
Referanslar
Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta paediatrica. 2006;95(1):6–14.
Waters D, Adeloye D, Woolham D, et al. Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. Journal of global health. 2018;8(2):021102.
Lichter-Konecki U, Caldovic L, Morizono H, et al. Ornithine transcarbamylase deficiency. 2022.
Ferreira CR, Rahman S, Keller M, et al. An international classification of inherited metabolic disorders (ICIMD). Journal of inherited metabolic disease. 2021;44(1):164–177.
J-M Saudubray, Á García-Cazorla, General Principles: Clinical Approach to Inborn Errors of Metabolism in Paediatrics. In: Saudubray JM, Baumgartner MR, Garcia-Cazorla A, et al. (eds.). Inborn Metabolic Diseases. Berlin, Germany: Springer; 2022. p. 6–10.
Peters B, Dattner T, Schlieben LD, et al. Disorders of vesicular trafficking presenting with recurrent acute liver failure: NBAS, RINT1, and SCYL1 deficiency. Journal of Inherited Metabolic Disease. 2025;48(1):e12707.
Iyer NS, Gimovsky AC, Ferreira CR, et al. Lysosomal storage disorders as an etiology of nonimmune hydrops fetalis: A systematic review. Clinical genetics. 2021;100(5):493–503.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. Journal of inherited metabolic disease. 2019;42(6):1192–1230.
J Häberle and V Rubio, Disorders of Ammonia Detoxification. In: Blau N, Dionisi Vici C, Ferreira CR, et al. (eds.). Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. 2nd ed. Switzerland: Springer; 2022. p. 263–289.
Moey LH, Azize NAA, Yakob Y, et al. Fructose-1, 6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: clinical and molecular findings in Malaysian patients. Pediatrics & Neonatology. 2018;59(4):397–403.
Merritt 2nd JL, MacLeod E, Jurecka A, et al. Clinical manifestations and management of fatty acid oxidation disorders: Merritt et al. Reviews in Endocrine and Metabolic Disorders. 2020;21(4):479–493.
Ferreira CR, Cassiman D, Blau N. Clinical and biochemical footprints of inherited metabolic diseases. II. Metabolic liver diseases. Molecular genetics and metabolism. 2019;127(2):117–121.
Cozma-Petrut A. The importance of neonatal screening for galactosemia. Nutrients; 2022.
Berry GT. Classic galactosemia and clinical variant galactosemia. 2021.
Das AM, Ballhausen D, Haas D, et al. Diagnosis, treatment, management and monitoring of patients with tyrosinaemia type 1: Consensus group recommendations from the German‐speaking countries. Journal of inherited metabolic disease. 2025;48(1):e12824.
Falsaperla R, Sciuto L, La Spina L, et al. Neonatal seizures as onset of Inborn Errors of Metabolism (IEMs): from diagnosis to treatment. A systematic review. Metabolic brain disease. 2021;36(8):2195–2203.
Coughlin CR, Tseng LA, Abdenur JE, et al. Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency. Journal of inherited metabolic disease. 2021;44(1):178–192.
Etchegaray A, Haffner D, Cruz SM, et al. Early Neonatal Fosdenopterin Treatment for Molybdenum Cofactor Deficiency Type A: New Insights into Its Natural History and Potential Role for Fetal Therapy. Journal of Clinical Medicine. 2025;14(10):3561.
Gburek‐Augustat J, Lee IC, Rubino M, et al. Sialidosis type I: How to alleviate disabling myoclonic seizures?—A multicenter analysis of eight cases and review of the literature. Epilepsia Open. 2026;11(2):577–591.
